132 related articles for article (PubMed ID: 21102324)
1. Neutropenia associated with rituximab therapy.
Grant C; Wilson WH; Dunleavy K
Curr Opin Hematol; 2011 Jan; 18(1):49-54. PubMed ID: 21102324
[TBL] [Abstract][Full Text] [Related]
2. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.
Tesfa D; Palmblad J
Expert Rev Hematol; 2011 Dec; 4(6):619-25. PubMed ID: 22077526
[TBL] [Abstract][Full Text] [Related]
3. [Late-onset neutropenia following rituximab therapy as a treatment of diffuse large B-cell lymphoma: a single institution study].
Kim M; Lee JK; Hong YJ; Hong SI; Kang HJ; Chang YH
Korean J Lab Med; 2010 Dec; 30(6):575-9. PubMed ID: 21157141
[TBL] [Abstract][Full Text] [Related]
4. Neutropenia after rituximab treatment: new insights on a late complication.
Wolach O; Shpilberg O; Lahav M
Curr Opin Hematol; 2012 Jan; 19(1):32-8. PubMed ID: 22080846
[TBL] [Abstract][Full Text] [Related]
5. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
Wolach O; Bairey O; Lahav M
Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-associated neutropenia.
Dunleavy K; Tay K; Wilson WH
Semin Hematol; 2010 Apr; 47(2):180-6. PubMed ID: 20350665
[TBL] [Abstract][Full Text] [Related]
7. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
Dunleavy K; Hakim F; Kim HK; Janik JE; Grant N; Nakayama T; White T; Wright G; Kwak L; Gress R; Tosato G; Wilson WH
Blood; 2005 Aug; 106(3):795-802. PubMed ID: 15718416
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.
Besada E; Koldingsnes W; Nossent J
QJM; 2012 Jun; 105(6):545-50. PubMed ID: 22301823
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.
Li SC; Chen YC; Evens AM; Lee CC; Liao HF; Yu CC; Tung YT; Su YC
Am J Hematol; 2010 Oct; 85(10):810-2. PubMed ID: 20730791
[TBL] [Abstract][Full Text] [Related]
10. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.
Nitta E; Izutsu K; Sato T; Ota Y; Takeuchi K; Kamijo A; Takahashi K; Oshima K; Kanda Y; Chiba S; Motokura T; Kurokawa M
Ann Oncol; 2007 Feb; 18(2):364-9. PubMed ID: 17079695
[TBL] [Abstract][Full Text] [Related]
11. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.
Tesfa D; Ajeganova S; Hägglund H; Sander B; Fadeel B; Hafström I; Palmblad J
Arthritis Rheum; 2011 Aug; 63(8):2209-14. PubMed ID: 21560117
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.
Arai Y; Yamashita K; Mizugishi K; Nishikori M; Hishizawa M; Kondo T; Kitano T; Kawabata H; Kadowaki N; Takaori-Kondo A
Hematology; 2015 May; 20(4):196-202. PubMed ID: 25130775
[TBL] [Abstract][Full Text] [Related]
13. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
14. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.
Terrier B; Ittah M; Tourneur L; Louache F; Soumelis V; Lavie F; Casadevall N; Candon S; Hummel A; Mariette X; Buzyn A
Haematologica; 2007 Feb; 92(2):e20-3. PubMed ID: 17405749
[TBL] [Abstract][Full Text] [Related]
15. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
Aguiar-Bujanda D; Blanco-Sánchez MJ; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura-Grau S; Bohn-Sarmiento U
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):761-5. PubMed ID: 26319620
[TBL] [Abstract][Full Text] [Related]
16. Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation--single-center study.
Ishida H; Inui M; Furusawa M; Tanabe K
Transpl Immunol; 2013 Mar; 28(2-3):93-9. PubMed ID: 23353568
[TBL] [Abstract][Full Text] [Related]
17. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas.
Tesfa D; Sander B; Lindkvist H; Nilsson C; Kimby E; Hägglund H; Wahlin BE; Klimkowska M; Palmblad J
Med Oncol; 2021 May; 38(6):70. PubMed ID: 34003398
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.
Parodis I; Söder F; Faustini F; Kasza Z; Samuelsson I; Zickert A; Svenungsson E; van Vollenhoven RF; Malmström V; Wermeling F; Gunnarsson I
Lupus; 2018 Aug; 27(9):1470-1478. PubMed ID: 29783918
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia.
Stamatopoulos K; Papadaki T; Pontikoglou C; Athanasiadou I; Stavroyianni N; Bux J; Batsis I; Pyrovolaki K; Paterakis G; Anagnostou D; Anagnostopoulos A; Papadaki HA
Leukemia; 2008 Jul; 22(7):1446-9. PubMed ID: 18185527
[No Abstract] [Full Text] [Related]
20. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
